Pritchard Veterinary Medical Teaching Hospital, University of California-Davis, CA, USA.
Equine Vet J. 2012 Sep;44(5):594-9. doi: 10.1111/j.2042-3306.2011.00530.x. Epub 2011 Dec 30.
Mesenchymal stem cells (MSCs) are commonly injected intralesionally for treatment of soft tissue injuries in the horse. Alternative routes of administration would be beneficial for treatment of lesions that cannot be accessed directly or to limit needle-induced iatrogenic damage to the surrounding tissue.
The purpose of our study was to evaluate MSC distribution after intra-arterial (IA) and intravenous (IV) regional limb perfusions (RLP) using scintigraphy. We hypothesised that MSCs would persist in the distal limb after tourniquet removal and that both techniques would lead to diffuse MSC distribution.
Six horses were used in the study. MSCs were labelled with hexamethyl propylene amine oxime (HMPAO) and technetium-99m. RLP was performed through the median artery of one forelimb and the cephalic vein of the opposite limb under general anaesthesia. The tourniquet was left in place for 45 min. Scintigraphic images were obtained at 0, 45, 75 min, 6 h and 24 h post injection.
Distribution of labelled MSCs through the entire distal limb was achieved with all 6 IA RLP, but 3 out of 6 IV RLP showed poor or absent uptake distal to the metacarpus. Mesenchymal stem cell persistence was 39% (30-60%) and 28% (14-50%) (median [minimum-maximum]) at 6 h for IA and IV RLP, respectively. Severe arterial thrombosis occurred in one horse after IA RLP.
Both IA and IV RLP of the distal limb result in MSC persistence in perfused tissues. The IA perfusion resulted in more reliable cell distribution to the pastern and foot area.
Regional limb perfusion of MSCs might be used in cases where intralesional injection is not possible or in order to avoid iatrogenic needle damage. Further work is needed to assess the safety of IA RLP before its clinical use.
间充质干细胞(MSCs)通常被注射到病变内,用于治疗马的软组织损伤。替代给药途径对于治疗无法直接触及的病变或限制针引起的周围组织医源性损伤将是有益的。
我们的研究目的是使用闪烁扫描术评估 MSC 经动脉内(IA)和静脉内(IV)区域性肢体灌注(RLP)后的分布。我们假设,在去除止血带后,MSC 将在远端肢体中持续存在,并且这两种技术都会导致 MSC 弥散分布。
本研究使用了 6 匹马。将 HMPAO 和 Tc-99m 标记 MSC。在全身麻醉下,通过前肢的正中动脉和对侧肢体的头静脉进行 RLP。止血带放置 45 分钟。注射后 0、45、75 分钟、6 小时和 24 小时获取闪烁扫描图像。
通过 6 次 IA RLP 实现了整个远端肢体的标记 MSC 分布,但 6 次 IV RLP 中有 3 次显示掌骨远端摄取不良或缺乏。IA 和 IV RLP 在 6 小时时 MSC 持续存在率分别为 39%(30-60%)和 28%(14-50%)(中位数[最小-最大])。IA RLP 后 1 匹马发生严重动脉血栓形成。
IA 和 IV RLP 均可使 MSC 持续存在于灌注组织中。IA 灌注可更可靠地将细胞分布到系部和足部区域。
MSCs 区域性肢体灌注可能用于无法进行病变内注射或避免医源性针损伤的情况。在临床应用之前,需要进一步研究 IA RLP 的安全性。